Marei Hany E, Bedair Khaled, Hasan Anwarul, Al-Mansoori Layla, Caratelli Sara, Sconocchia Giuseppe, Gaiba Alice, Cenciarelli Carlo
Department of Cytology and Histology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35116, Egypt.
Department of Social Sciences, College of Arts and Sciences, Qatar University, P.O. Box 2713, Doha, Qatar.
Cancer Cell Int. 2025 Jan 4;25(1):3. doi: 10.1186/s12935-024-03615-8.
Breast cancer will overtake all other cancers in terms of diagnoses in 2024. Breast cancer counts highest among women in terms of cancer incidence and death rates. Innovative treatment approaches are desperately needed because treatment resistance brought on by current clinical drugs impedes therapeutic efficacy. The T cell-based immunotherapy known as chimeric antigen receptor (CAR) T cell treatment, which uses the patient's immune cells to fight cancer, has demonstrated remarkable efficacy in treating hematologic malignancies; nevertheless, the treatment effects in solid tumors, like breast cancer, have not lived up to expectations. We discuss in detail the role of tumor-associated antigens in breast cancer, current clinical trials, barriers to the intended therapeutic effects of CAR-T cell therapy, and potential ways to increase treatment efficacy. Finally, our review aims to stimulate readers' curiosity by summarizing the most recent advancements in CAR-T cell therapy for breast cancer.
到2024年，乳腺癌的诊断数量将超过所有其他癌症。在癌症发病率和死亡率方面，乳腺癌在女性中占比最高。由于目前临床药物导致的治疗耐药性阻碍了治疗效果，因此迫切需要创新的治疗方法。基于T细胞的免疫疗法，即嵌合抗原受体（CAR）T细胞治疗，利用患者的免疫细胞对抗癌症，在治疗血液系统恶性肿瘤方面已显示出显著疗效；然而，在实体瘤（如乳腺癌）中的治疗效果却不尽人意。我们详细讨论了肿瘤相关抗原在乳腺癌中的作用、当前的临床试验、CAR-T细胞疗法预期治疗效果的障碍以及提高治疗效果的潜在方法。最后，我们的综述旨在通过总结CAR-T细胞疗法治疗乳腺癌的最新进展，激发读者的好奇心。
Zotero 插件
